CalciMedica (NASDAQ:CALC – Get Free Report) is projected to release its resultson Wednesday, November 11th. Analysts expect CalciMedica to post earnings of ($1.2750) per share for the quarter.
CalciMedica (NASDAQ:CALC – Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.97. On average, analysts expect CalciMedica to post ($5.25) EPS for the current fiscal year and ($3.15) EPS for the next fiscal year.
CalciMedica Stock Up 11.4%
CALC stock opened at $1.51 on Tuesday. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.58 and a quick ratio of 5.58. The stock has a market capitalization of $10.35 million, a price-to-earnings ratio of -0.22 and a beta of 0.84. The business’s fifty day moving average price is $1.60 and its two-hundred day moving average price is $3.50. CalciMedica has a fifty-two week low of $1.00 and a fifty-two week high of $36.00.
Analysts Set New Price Targets
View Our Latest Analysis on CalciMedica
CalciMedica Company Profile
CalciMedica, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which help regulate immune-cell activation and inflammatory responses.
CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being evaluated as a potential treatment for acute inflammatory conditions, including severe acute pancreatitis and associated organ injury.
Read More
- Five stocks we like better than CalciMedica
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for CalciMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CalciMedica and related companies with MarketBeat.com's FREE daily email newsletter.
